Cytokinetics Posts $25M in Aficamten Sales as Non-Obstructive HCM Expansion Looms
Event summary
- $25.3M in Q2 revenue from MYQORZO (aficamten), up from $0 in prior-year period.
- ACACIA-HCM trial met primary endpoints for non-obstructive HCM, setting stage for supplemental NDA filing in Q4 2026.
- $1.7B cash position as of June 30, 2026, following $760M equity offering at $71/share.
- MYQORZO launched in Germany, approved in UK, with regulatory reviews ongoing in Canada, Switzerland, Hong Kong and Taiwan.
The big picture
Cytokinetics is transitioning from a development-stage biotech to a commercial player with MYQORZO, while positioning aficamten as a potential franchise product across hypertrophic cardiomyopathy subtypes. The $760M capital raise suggests confidence in both near-term commercialization and longer-term pipeline expansion, particularly in heart failure indications where cardiac myosin modulators represent a growing therapeutic category.
What we're watching
- Regulatory Momentum
- Whether Cytokinetics can secure non-obstructive HCM approval by mid-2027, expanding MYQORZO's addressable market.
- Commercial Execution
- The pace at which international launches proceed post-Germany and UK approvals.
- Pipeline Valuation
- How investors price the company's $1.7B cash position against its expanding clinical portfolio.